Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neuren Pharmaceuticals Limited (NURPF – Research Report), GlaxoSmithKline (GSK – Research Rep ...

Bristol-Myers Squibb has teamed up with BioNTech to co-develop a bispecific antibody, BNT327, targeting multiple solid tumors ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

German-based BioNTech , best known for its collaboration with Pfizer during the COVID-19 pandemic for developing vaccines, ...

This decision came after the company entered into an agreement with Bristol Myers Squibb for the co-development and ...

In the assessment of 12-month price targets, analysts unveil insights for BioNTech, presenting an average target of $138.7, a ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

Coming off the S&P 500’s best May in 35 years, the benchmark edged up at the start of what’s historically one of its quietest ...